1Ran Q, Williamson SR,Zhang S, el al. TFE3 break-apart FISt l has a higher sensitivity for Xpl h 2 translocation-associated renal cell carcinoma compared with TFE3 or eathepsin K immunohistoehemieal staining alone: expanding the mnrphnlngie speetrnm[ J ]. Am J Surg Pathol, 2013,37:804-815.
2Song HC, Sun N, Zhang WP, et al. Biological characteristics of pedi- atric renal cell carcinoma associated with Xpl 1,2 translocations/TFE3 gene fusions[J]. J Pediatr Surg ,2014,49(4) : 539 -542.
3Muller- Hocker J, Babaryka G, Schmid I, et al. Overexpression of cyclinD1, D3, and p21 in an infantile renal carcinoma with Xp11,2/ TFE3 - gene fusion [,i]. Pathol Res Pract, 2008, 204 (8) :589 - 597.
4Hirobe M, Masumori N, Tanaka T, et al. Establishment of an ASPL - TFE3 renal cell carcinoma cell line ( S - TFE) [ J]. Cancer Biol T- her, 2013,14(6) :502 -510.
5Ellis CL, Eble .IN, Subhawong AP, et al. Clinical heterogeneity of Xpll translocation renal cell carcinoma: impact of fusion subtype, age,and stage[,i]. Mod Pathol, 2014,27(6) :875 -886.
6Clark J, Lu Y'I, Sidhar SK, et al. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcino- ma[ J]. Oneogene, 1997, 15 (18) :2233 - 2239.
7Argani P, Lui MY, Couturier 'i, et al. A novel CLTC - TFE3 gene fusion in pediatric renal adenocarcinoma with t ( X ; 17 ) ( pl 1,2 ; q23 ) [J]. Oncogene, 2003, 22(34):5374-5378.
8Zhong M, De Angelo P, Osborne L,et al. Dual -color, break -apart FISH assay on paraffin embedded tissues as an adjunct to diagnosis of Xpl 1 translocation renal cell carcinoma and alveolar soft part sarcoma [J]. Am J SurgPathol, 2010, 34:757 -766.
9Armah HB, Parwani AV, Surti U, et al. Xpll. 2 translocation renal cell carcinoma occurring during pregnancy with a novel translocation involving chromosome 19 : a case report with review of the literature [J]. DiagnPathol, 2009 ,4(1):1-15.
10Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signa- ling by transcriptional up - regulation, defining another class of tumors as candidates for therapeutic MET inhibition[ J]. Cancer Res,2007, 67(3) :919 -929.
